Electra Therapeutics, Inc. (ETRA) – What Are Brokerages Thinking About This Stock?

Electra Therapeutics, Inc. (NASDAQ:ETRA) has been assigned a consensus rating of “Buy” from the five brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $34.00.

A number of research firms recently weighed in on ETRA. Jefferies Financial Group started coverage on Electra Therapeutics in a report on Tuesday. They set a “buy” rating and a $32.00 target price on the stock. Cantor Fitzgerald started coverage on Electra Therapeutics in a research note on Tuesday. They issued an “overweight” rating on the stock. Wall Street Zen raised Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. Zacks Research raised Electra Therapeutics to a “hold” rating in a report on Wednesday. Finally, TD Cowen assumed coverage on shares of Electra Therapeutics in a research report on Tuesday. They set a “buy” rating for the company.

Electra Therapeutics Stock Performance

NASDAQ ETRA opened at $8.75 on Friday. Electra Therapeutics has a 12 month low of $8.50 and a 12 month high of $15.50.

Insider Buying and Selling at Electra Therapeutics

In other Electra Therapeutics news, Director Carl Gordon purchased 1,333,333 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the director owned 5,126,891 shares in the company, valued at $76,903,365. The trade was a 35.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc purchased 1,333,333 shares of the company’s stock in a transaction dated Monday, September 21st. The stock was acquired at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the director owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This represents a 35.15% increase in their position. The disclosure for this purchase is available in the SEC filing.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.